ZYLOXTB (02190) intends to further acquire 11% equity stake in Optimed Holding GmbH.

ZYLOXTB (02190) has announced the acquisition of 49% equity stake in the target company Optimed Holding GmbH. On March 17, 2026, the company issued a notice exercising the subscription option to further acquire an additional 11% equity stake in the target company. After exercising the option, the company is required to acquire the remaining 40% equity stake in the target company in the first half of 2028. After exercising the option, the target company will become a subsidiary of the company, and the financial performance of the target company will be consolidated into the company's financial statements. The target group is mainly engaged in the development, manufacturing, and distribution of medical technology products, instruments, and solutions. Within the target group, the wholly-owned subsidiary of the target company, Optimed Medizinische Instrumente GmbH (Optimed), is its main operating subsidiary. The company is headquartered in Erlangen, Germany, and is dedicated to the research, development, manufacturing, and global distribution of high-quality medical products for minimally invasive vascular and urological surgery. Optimed has the most complete product portfolio in the peripheral venous stent market, including instruments for the iliac vein, the bifurcation of the iliac artery, the inferior vena cava, and the aorta.